Solara's strong Q4 lifts FY26 finish but ibuprofen drag forces strategic review

The Ibuprofen business posted a negative EBITDA of Rs. 179 million in Q4 despite revenue rising 61% year-on-year to Rs. 849 million

Solara announces closure of US FDA inspection at Puducherry facility

The Puducherry facility, dedicated to Ibuprofen and its derivatives, is equipped with advanced infrastructure to serve both domestic and international markets

Solara Active Pharma dispatches final rights share call notice; Rs 112.5 per share due by May 7

API maker begins circulation of second and final call money notice for partly paid-up rights shares, completing the last leg of its 2024 fundraising cycle

Solara’s Mangalore facility clears FDA inspection with VAI status

Solara Active Pharma Sciences posts Q2 FY26 consolidated loss at Rs. 10.10 Cr

Solara Active Pharma Sciences has reported total income of Rs. 314.03 crore during the period ended September 30, 2025

Solara Active Pharma Sciences consolidated Q1FY26 PAT rises to Rs. 10.52 Cr

Solara Active Pharma Sciences has reported total income of Rs. 320.13 crores during the period ended June 30, 2025

Solara Active Pharma Sciences posts Q4 FY25 consolidated loss at Rs. 2.10 Cr

The company has posted net profit of Rs. 0.54 crores for the Financial Year ended March 31, 2025

Solara Active Pharma Sciences reports consolidated Q2 FY25 net profit at Rs. 8.01 Cr

Solara Active Pharma Sciences has reported total income of Rs. 347.27 crores during the period ended September 30, 2024

Solara Active Pharma Sciences reports Q1 FY25 consolidated loss at Rs. 13.46 Cr

Solara Active Pharma Sciences has reported total income of Rs. 364.05 crores during the period ended June 30, 2024

Solara Active Pharma elevates Arun Kumar Baskaran to the post of CFO

Arun is currently working as Vice President (Strategy) in Solara leading Business finance & Strategy function